At a glance overview of the worldwide impact of depression, focusing on various aspects such as its prevalence, economic burden, treatment challenges, and emerging research areas.
The infographic shows a 27% increase in depression cases due to COVID-19, affecting 280 million people worldwide. The economic impact in the U.S. reached $326 billion in 2018, a 35% increase since 2010. About 30% of those with Major Depressive Disorder (MDD) are resistant to standard treatments. There’s growing interest in psychedelic research for treating depression, focusing on their ability to activate brain receptors and promote neuroplasticity.
Related content
This slide deck summarizes the current knowledge surrounding the use of psychedelics for the treatment of depression. Specifically, our focus centers on serotonergic psychedelics, commonly referred to as classical psychedelics. These psychedelics primarily function as agonists or partial agonists at the serotonin 2A receptor (5-HT2A receptor).
Dr. Jasmina Mallet highlights the latest research in psychiatric genetics, emphasizing the role of Polygenic Risk Scores (PRS) in psychiatry.
This article discusses the latest advances in psychiatric genetics, focusing on MDD, the use of PRS in research, and potential future clinical practice applications.